Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab

Journal of Clinical Oncology

Volumn 28, Issue 20, 2010, Pages 3360-3365

  Barrans, Sharon ^a   Crouch, Simon ^a   Smith, Alex ^a   Turner, Kathryn ^a   Owen, Roger ^a   Patmore, Russell ^a   Roman, Eve ^a   Jack, Andrew ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MYC PROTEIN; PREDNISONE; PROTEIN BCL 2; PROTEIN BCL 6; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP PROTOCOL; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; AGE; GENETICS; MIDDLE AGED; MORTALITY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISONE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYC; TRANSLOCATION, GENETIC; VINCRISTINE;

EID: 77954752069     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2009.26.3947     Document Type: Article

References (40)

1. Swerdlow S, Campo E, Harris NL, et al: WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Lyon, France, IARC, 2008
2. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
3. Sehn LH, Berry B, Chhanabhai M, et al: The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109:1857-1861, 2007
4. Rosenwald A, Staudt LM: Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma 44:S41-S47, 2003 (suppl 3) (Pubitemid 38196062)
5. Alizadeh AA, Eisen MB, Davis RE, et al: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000 (Pubitemid 30082188)
6. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004 (Pubitemid 38029949)
7. Lossos IS, Czerwinski DK, Alizadeh AA, et al: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350:1828-1837, 2004
8. Iqbal J, Neppalli VT, Wright G, et al: BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol 24:961-968, 2006 (Pubitemid 46638851)
9. Barrans SL, Carter I, Owen RG, et al: Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99:1136-1143, 2002 (Pubitemid 34547064)
10. Barrans SL, Fenton JA, Banham A, et al: Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood 104:2933-2935, 2004 (Pubitemid 39434982)
11. Banham AH, Connors JM, Brown PJ, et al: Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. Clin Cancer Res 11:1065-1072, 2005 (Pubitemid 40175755)
12. Barrans SL, O'Connor SJ, Evans PA, et al: Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma. Br J Haematol 117:322-332, 2002 (Pubitemid 34451147)
13. Barrans SL, Evans PA, O'Connor SJ, et al: The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome. Clin Cancer Res 9:2133-2139, 2003 (Pubitemid 36687635)
14. Pasqualucci L, Compagno M, Houldsworth J, et al: Inactivation of the PRDM1/BLIMP1 gene in diffuse large B cell lymphoma. J Exp Med 203:311-317, 2006 (Pubitemid 43290840)
15. Tam W, Gomez M, Chadburn A, et al: Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood 107:4090-4100, 2006 (Pubitemid 43726818)
16. Mounier N, Briere J, Gisselbrecht C, et al: Rituximab plus CHOP (CHOP-R) overcomes bcl-2 - associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 101:4279-4284, 2003
17. Winter JN, Weller EA, Horning SJ, et al: Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: A prospective correlative study. Blood 107:4207-4213, 2006; Erratum in: Blood 109:2292, 2007
18. Nyman H, Adde M, Karjalainen-Lindsberg ML, et al: Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 109:4930-4935, 2007 (Pubitemid 46827791)
19. Kramer MH, Hermans J, Wijburg E, et al: Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92:3152-3162, 1998
20. Hummel M, Bentink S, Berger H, et al: A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419-2430, 2006 (Pubitemid 43855045)
21. Le Gouill S, Talmant P, Touzeau C, et al: The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement. Haematologica 92:1335-1342, 2007 (Pubitemid 350144150)
22. Niitsu N, Okamoto M, Miura I, et al: Clinical significance of 8q24/c-MYC translocation in diffuse large B-cell lymphoma. Cancer Sci 100:233-237, 2009
23. Tibiletti MG, Martin V, Bernasconi B, et al: BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: A multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. Hum Pathol 40:645-652, 2009
24. Tomita N, Tokunaka M, Nakamura N, et al: Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica 94:935-943, 2009
25. Obermann EC, Csato M, Dirnhofer S, et al: Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment. J Clin Pathol 62:754-756, 2009
26. Savage KJ, Johnson NA, Ben-Neriah S, et al: MYC gene re-arrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood 114:3533-3537, 2009
27. Johnson NA, Savage KJ, Ludkovski O, et al: Lymphomas with concurrent BCL2 and MYC translocations: The critical factors associated with survival. Blood 114:2273-2279, 2009
28. Mead GM, Barrans SL, Qian W, et al: A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 112:2248-2260, 2008
29. Smith A, Roman E, Howell D, et al: The Haematological Malignancy Research Network (HMRN): A new information strategy for population-based epidemiology and health service research. BJH 148:739-753, 2010
30. Cox DR: Regression Models and Life Tables. Journal of the Royal Statistical Society B 34:187-220, 1972
31. Therneau TM, Grambsch PM: Modeling Survival Data: Extending the Cox Model. New York, NY, Springer-Verlag, 2000
32. Little RJA, Rubin DB: Statistical Analysis with Missing Data (ed 2). Hoboken, NJ, Wiley Interscience, 2002
33. Dave SS, Fu K, Wright GW, et al: Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354:2431-2442, 2006 (Pubitemid 43855046)
34. Shachaf CM, Gentles AJ, Elchuri S, et al: Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance. Cancer Res 68:5132-5142, 2008
35. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
36. Choi WW, Weisenburger DD, Greiner TC, et al: A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res 15:5494-5502, 2009
37. Masir N, Campbell LJ, Goff LK, et al: BCL2 protein expression in follicular lymphomas with t(14; 18) chromosomal translocations. Br J Haematol 144:716-725, 2009
38. Wang K, Saito M, Bisikirska BC, et al: Genome-wide identification of post-translational modulators of transcription factor activity in human B cells. Nat Biotechnol 27:829-839, 2009
39. Klein U, Tu Y, Stolovitzky GA, et al: Transcriptional analysis of the B cell germinal center reaction. Proc Natl Acad Sci U S A 100:2639-2644, 2003 (Pubitemid 36297551)
40. Gaidano G, Ballerini P, Gong JZ, et al: p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 88:5413-5417, 1991 (Pubitemid 21914755)